What is Johnson & Johnson's simponi / simponi aria — sales to customers (note 9)?

Johnson & Johnson (JNJ) reported simponi / simponi aria — sales to customers (note 9) of $647.00M in Q1 2026.

How has Johnson & Johnson's simponi / simponi aria — sales to customers (note 9) changed year-over-year?

Johnson & Johnson's simponi / simponi aria — sales to customers (note 9) decreased by 1.8% year-over-year, from $659.00M to $647.00M.

What is the long-term trend for Johnson & Johnson's simponi / simponi aria — sales to customers (note 9)?

Over 4 years (2021 to 2025), Johnson & Johnson's simponi / simponi aria — sales to customers (note 9) has grown at a 4.1% compound annual growth rate (CAGR), from $2.28B to $2.67B.

What does simponi / simponi aria — sales to customers (note 9) mean?

The total net revenue generated from the sales of Simponi and Simponi Aria biologic therapies.

Products & Services · Sales to customers (Note 9)

SIMPONI / SIMPONI ARIA — Sales to customers (Note 9)

Johnson & Johnson SIMPONI / SIMPONI ARIA — Sales to customers (Note 9) increased by 2.4% to $647.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 1.8%, from $659.00M to $647.00M. Over 4 years (FY 2021 to FY 2025), SIMPONI / SIMPONI ARIA — Sales to customers (Note 9) shows an upward trend with a 4.1% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.

Analysis

StatementSegment

CategoryGrowth

SignalHigher is better

VolatilityModerate

First reportedQ1 2017

Last reportedQ1 2026Apr 22, 2026

Rolls up toTotal Revenue

How to read this metric

An increase indicates strong market adoption and sustained demand for the therapy, while a decrease may signal increased competition from biosimilars or a shift in clinical treatment standards.

Detailed definition

This metric represents the total net revenue generated from the sale of Simponi and Simponi Aria, which are biologic the...

Peer comparison

Comparable to revenue metrics for specific biologic or specialty pharmaceutical product lines at peer companies like AbbVie or Amgen.

Metric ID: jnj_segment_simponi_simponi_aria_sales_to_customers_note_9

Historical Data

20 periods

	Q2 '21	Q3 '21	Q4 '21	Q1 '22	Q2 '22	Q3 '22	Q4 '22	Q1 '23	Q2 '23	Q3 '23	Q4 '23	Q1 '24	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Value	$584.00M	$571.00M	$559.00M	$571.00M	$566.00M	$545.00M	$502.00M	$537.00M	$529.00M	$629.00M	$502.00M	$554.00M	$537.00M	$516.00M	$583.00M	$659.00M	$690.00M	$687.00M	$632.00M	$647.00M
QoQ Change	—	-2.2%	-2.1%	+2.1%	-0.9%	-3.7%	-7.9%	+7.0%	-1.5%	+18.9%	-20.2%	+10.4%	-3.1%	-3.9%	+13.0%	+13.0%	+4.7%	-0.4%	-8.0%	+2.4%
YoY Change	—	—	—	—	-3.1%	-4.6%	-10.2%	-6.0%	-6.5%	+15.4%	+0.0%	+3.2%	+1.5%	-18.0%	+16.1%	+19.0%	+28.5%	+33.1%	+8.4%	-1.8%

Range$502.00M – $690.00M

CAGR+2.2%

Avg YoY Growth+4.7%

Median YoY Growth+0.8%

Similar Metrics at Other Companies

BiogenBIIB View metric

InsmedINSM View metric

Frequently Asked Questions

What is Johnson & Johnson's simponi / simponi aria — sales to customers (note 9)?: Johnson & Johnson (JNJ) reported simponi / simponi aria — sales to customers (note 9) of $647.00M in Q1 2026.
How has Johnson & Johnson's simponi / simponi aria — sales to customers (note 9) changed year-over-year?: Johnson & Johnson's simponi / simponi aria — sales to customers (note 9) decreased by 1.8% year-over-year, from $659.00M to $647.00M.
What is the long-term trend for Johnson & Johnson's simponi / simponi aria — sales to customers (note 9)?: Over 4 years (2021 to 2025), Johnson & Johnson's simponi / simponi aria — sales to customers (note 9) has grown at a 4.1% compound annual growth rate (CAGR), from $2.28B to $2.67B.
What does simponi / simponi aria — sales to customers (note 9) mean?: The total net revenue generated from the sales of Simponi and Simponi Aria biologic therapies.